VBI Vaccines Inc
F:LO9A
VBI Vaccines Inc
F:LO9A
Price:
0.0845
EUR
Market Cap:
€2m
Relative Value
There is not enough data to reliably calculate the relative value of LO9A.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
LO9A
Relative Value
Base Case
Not Available
Multiples Across Competitors
LO9A Competitors Multiples
VBI Vaccines Inc Competitors
VBI Vaccines Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
VBI Vaccines Inc
F:LO9A
|
808.8k EUR | 0.1 | -0 | 0.2 | 0.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
412.6B USD | 6.7 | 97.9 | 16 | 22.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
207.9B USD | 5.5 | 26.1 | 15 | 15 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
181.7B USD | 6.2 | 21.4 | 13.3 | 16.4 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121.3B USD | 10.1 | 30.6 | 23.1 | 24.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.8B USD | 5.7 | 18.2 | 13.7 | 15.6 | |
| AU |
|
CSL Ltd
ASX:CSL
|
70B AUD | 3.2 | 35.5 | 11.7 | 14.7 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.4B EUR | 11.2 | 36.1 | 39.3 | 40.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
